How Food Labels and Dietary Guidelines Fuel Insulin Resistance

As caregivers, we do our best to make the healthiest choices for our loved ones and ourselves. But what happens when the very labels we trust — “sugar-free,” “heart-healthy,” “low-fat” — are leading us down a path of worsening insulin resistance and cognitive decline? This eye-opening article explores the hidden dangers of modern food labeling and how they contribute to conditions like Alzheimer’s, diabetes, and obesity — reminding us that protecting memory and metabolic health starts with knowing what’s really in our food.

(Note: About Us, a reference bibliography, related books, videos and apps can be found at the end of this article.)

The Role of GLP-1 Drugs in Managing Type 2 Diabetes, Obesity and Dementia

Once a niche medication for managing type 2 diabetes, Ozempic has rapidly become a cultural phenomenon—celebrated for dramatic weight loss, criticized for contributing to drug shortages, and now attracting attention for a far more audacious possibility: could it help prevent Alzheimer’s disease? As media buzz collides with pharmaceutical marketing and genuine scientific curiosity, it’s worth asking: how much of this excitement is backed by evidence?

At the heart of the conversation are glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs that has fundamentally changed the treatment landscape for both diabetes and obesity. Semaglutide—sold as Ozempic—is among the most potent and promising. While its effectiveness in improving blood sugar control and reducing cardiovascular risk is well established, new research hints at broader effects, including potential neuroprotective benefits. This article examines the science, speculation, and reality behind one of the most widely discussed drugs in modern medicine.

(Note: About Us, a reference bibliography, related books and videos are all found at the end of this article.)